Management Team

Leo Redmond, MBA, President & Chief Financial Officer: Mr. Redmond has more than 20 years experience in the life sciences industry. Prior to Presidio, Mr. Redmond served as Senior Director of Finance at Genentech with a broad range of responsibilities including leadership of financial planning, corporate accounting, financial operations and reporting functions, and supporting the corporate, R&D, commercial and business development organizations. He led the collaborations finance and corporate financial systems, and engaged in negotiation and subsequent administration of multiple business development arrangements. Mr. Redmond also served as the CFO and Secretary for the Genentech Foundation for Biomedical Sciences.

Mr. Redmond holds a BS degree, with a double major in Business Administration and Accounting, with honors, from the University of Kansas and an MBA from the Anderson School of Management at UCLA.

Richard Colonno, PhD, Chief Scientific Adviser: Dr. Colonno is a molecular virologist with over 30 years experience in the pharmaceutical industry and is an internationally recognized expert in the areas of antiviral drug discovery and viral resistance. As co-author of over 150 original scientific articles on a wide variety of RNA and DNA viruses, he has advanced several antiviral compounds targeting HIV, HBV and HCV into clinical trials. Prior to joining Presidio, Dr. Colonno led the antiviral drug discovery efforts as Vice President, Infectious Diseases Drug Discovery at Bristol-Myers Squibb and as Senior Director of Antiviral Research at Merck Research Labs. Dr. Colonno played a key leadership role in the identification, advancement and worldwide approval of the HIV protease inhibitor Reyataz™ (atazanavir) and the HBV polymerase inhibitor Baraclude™ (entecavir). Dr. Colonno holds a PhD in Microbiology from the University of Kansas.

Nathaniel Brown, MD, Chief Medical Adviser: Dr. Brown is an Infectious Diseases physician with over 20 years of pharmaceutical development experience, with leadership roles in U.S. and global product registration programs for six antiviral/anti-infective medicines for hepatitis B, hepatitis C, HIV/AIDS, and associated infections. He has extensive experience with global drug development, including North and South America, Europe, India, Southeast Asia, and China. Previous positions include: Executive VP and Chief Medical Officer at Idenix Pharmaceuticals; and Director, Clinical and Scientific Affairs, Hepatitis, at Glaxo Wellcome, as well as academic positions at UCLA and Cornell. Dr. Brown has served in advisory roles for the Hepatitis B Foundation, the U.S. Food and Drug Administration, various pharma/biotech companies, and venture/equity organizations.

Dr. Brown studied Molecular Biophysics and Biochemistry at Yale and received his MD from the Georgetown School of Medicine, with subsequent clinical training at Cornell Medical Center and post-doctoral research training (Infectious Diseases & Virology) at Yale School of Medicine.

Leping Li, PhD, Chemistry Adviser: Dr. Li has over 20 years of drug discovery and early development experience with large pharma and early-stage biotech companies. Prior to joining Presidio, he was Scientific Director in Medicinal Chemistry at Amgen, where he received the 2004 Robert A. Swanson Distinguished Employee Award. Before Amgen, Dr. Li served as a Research Investigator at Abbott Laboratories. In his drug development career, he has led project teams and advanced multiple programs from early lead identification to clinical development across several therapeutic areas, including infectious diseases, cancers and metabolic disorders.

Dr. Li obtained his BS degree in Chemistry from Shandong University in China. As a recipient of a China-US exchange scholarship (the Chemistry Graduate Program), he attended Rice University earning his Ph.D. degree in Organic Chemistry. Dr. Li also conducted postdoctoral research at Stanford University.

Eric Ruby, MS, Regulatory Affairs Adviser: Mr. Ruby has more than 20 years of experience in regulatory strategy, data review, and communications with regulatory agencies. He previously served as Senior Director, Regulatory Affairs at Alnylam Pharmaceuticals, and Senior Director, Regulatory Affairs, at Vertex Pharmaceuticals. At Vertex, Mr Ruby led global regulatory communications for the hepatitis C drug Incivek™ (telaprevir) from the initial clinical trial through Phase 2b, as well as numerous other projects. During his career he has led or supervised regulatory strategies and agency interactions for more than 15 drug development programs. Prior to joining the pharmaceutical industry, Mr. Ruby held positions with the U.S. FDA, as a chemistry reviewer and as a manager for review of drug metabolism and PK studies.

Mr. Ruby earned his BA degree in Chemistry at Harvard University, and an MS degree in Organic Chemistry at the University of California, Berkeley.